SCHEMBL26268476

SCHEMBL26268476

Cc1cccn1C1CCC(C)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 4/20 0.36
▸ POLB P06746 1/20 0.36
▸ MEN1 O00255 5/20 0.35
▸ KMT2A Q03164 5/20 0.35
▸ TSHR P16473 2/20 0.35
▸ PKM P14618 2/20 0.35
▸ USP2 O75604 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ CYP11B2 P19099 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ OPRM1 P35372 1/20 0.32
▸ OPRD1 P41143 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ OPRL1 P41146 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28810704 0.93 LMNA (0.35) ACHEPOLBMEN1KMT2ATSHR
SCHEMBL13783352 0.92 — —
SCHEMBL8139572 0.82 SLC18A3 (0.39) GAAALDH1A1HPGDALOX15
SCHEMBL26269430 0.80 GAA (0.40) GAASMN1; SMN2DRD2DRD4DRD3
SCHEMBL8269036 0.73 MEN1 (0.40) ACHEPOLBMEN1KMT2ATSHR
SCHEMBL8339813 0.73 MEN1 (0.40) ACHEPOLBMEN1KMT2ATSHR
SCHEMBL20689300 0.73 MEN1 (0.44) POLBMEN1KMT2AUSP2GAA
SCHEMBL28153999 0.72 IDH1 (0.40) ALDH1A1
SCHEMBL18161061 0.70 KMT2A (0.46) ACHEMEN1KMT2AUSP2GAA
SCHEMBL8143998 0.69 OPRK1 (0.30) DRD2DRD4DRD3OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 ACHE 3607/4885POLB 1072/4885MEN1 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback